HRT Financial’s Summit Therapeutics SMMT Stock Holding History

HRT Financial’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.88M	Buy	+197,653	New	+$3.5M	0.01%	1484
2025 Q3	–	Sell	-241,685	Closed	-$5.14M	–	3595
2025 Q2	$5.14M	Buy	+241,685	New	+$5.51M	0.02%	529
2023 Q2	–	Sell	-397,903	Closed	-$696K	–	3211
2023 Q1	$696K	Buy	397,903 +359,477	+936%	+$980K	0.01%	1164
2022 Q4	$163K	Buy	+38,426	New	+$69.9K	﹤0.01%	1982
2021 Q2	–	Sell	-29,906	Closed	-$175K	–	3471
2021 Q1	$175K	Buy	+29,906	New	+$193K	﹤0.01%	2347
2020 Q4	–	Sell	-18,119	Closed	-$62K	–	2409
2020 Q3	$62K	Buy	+18,119	New	+$62.7K	﹤0.01%	1630

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

HRT Financial's SMMT Position: Q2 2026 in Review

HRT Financial opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 197,653 shares worth $2.88M. The stake represents 0.01% of the portfolio and ranks #1484 among its holdings. This is a return to the name: HRT Financial previously reported a position in SMMT as recently as Q2 2025.

HRT Financial first reported a position in SMMT in Q3 2020 and has held it in 6 quarters since. The position peaked at $5.14M in Q2 2025. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

HRT Financial held 197,653 shares of Summit Therapeutics worth $2.88M as of Q2 2026.
Summit Therapeutics was a new HRT Financial position in Q2 2026.
Summit Therapeutics made up 0.01% of HRT Financial's portfolio in Q2 2026, its #1484 holding.
HRT Financial first reported a position in Summit Therapeutics in Q3 2020 and has held it in 6 quarters since.
HRT Financial's Summit Therapeutics position peaked at $5.14M in Q2 2025.
243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.